Prognostic Value of HALP Score in Rheumatic Mitral Stenosis: A Long‐Term Follow‐up Study

ABSTRACT Objective This study aimed to evaluate the prognostic value of the hemoglobin–albumin–lymphocyte–platelet (HALP) score in patients with rheumatic mitral stenosis (RMS). Methods A total of 169 patients with RMS were retrospectively analyzed over a median follow‐up period of 124 months (IQR: 96–148). The primary endpoint was major adverse cardiac and cerebrovascular events (MACCE). The predictive performance of the HALP score was assessed using receiver operating characteristic (ROC) analysis, Cox regression, and Kaplan–Meier survival analysis. Results The HALP score demonstrated a modest but statistically significant ability to predict MACCE (AUC = 0.644, p = 0.037). The optimal cut‐off value was 35.65, with a sensitivity of 60.4% and specificity of 38.1%. Patients with lower HALP scores had a significantly higher incidence of MACCE (log‐rank p = 0.015). However, in multivariable analysis, the HALP score was not identified as an independent predictor ( p = 0.076). Conclusion The HALP score may serve as a simple and cost‐effective complementary tool for risk stratification in patients with RMS. However, its prognostic value appears limited when used alone, and it should be interpreted alongside established clinical and echocardiographic parameters.